ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion

International Journal of Oncology

Volumn 40, Issue 5, 2012, Pages 1714-1724

  Xiao, Li Jie ^a,b   Lin, Ping ^a   Lin, Feng ^a   Liu, Xin ^a   Qin, Wei ^a   Zou, Hai Feng ^a   Guo, Liang ^a   Liu, Wei ^a   Wang, Shu Juan ^a   Yu, Xiao Guang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY   (China)

Author keywords

A disintegrin and metalloprotease 17; Matrix metalloproteinase 2 and 9; Prostatic adenocarcinomas; Transforming growth factor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANDROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ARTICLE; CANCER CELL; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; INFORMATION PROCESSING; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; UPREGULATION;

ADAM PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MALE; MAP KINASE KINASE KINASES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION; TRANSFORMING GROWTH FACTOR ALPHA; UP-REGULATION;

EID: 84860289206     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1320     Document Type: Article

References (49)

1. Society AC: Cancer facts and figures, 2009. Atlanta, American Society, 2009.
2. McCulloch DR, Harvey M and Herington AC: The expression of the ADAMs proteases in prostate cancer cell lines and their regulation by dihydrotestosterone. Mol Cell Endocrinol 167: 11-21, 2000.
3. Saleem M, Adhami VM, Zhong W, et al: A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 15: 217-227, 2006. (Pubitemid 43342167)
4. Saleem M, Kweon MH, Johnson JJ, et al: S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proc Natl Acad Sci USA 103: 14825-14830, 2006. (Pubitemid 44527813)
5. Blobel CP: ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 6: 32-43, 2005.
6. Edwards DR, Handsley MM and Pennington CJ: The ADAM metalloproteinases. Mol Aspects Med 29: 258-289, 2008.
7. Lu X, Lu D, Scully M and Kakkar V: ADAM proteins - therapeutic potential in cancer. Curr Cancer Drug Targets 8: 720-732, 2008.
8. Arribas J and Esselens C: ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des 15: 2319-2335, 2009.
9. Nath D, Slocombe PM, Stephens PE, et al: Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. J Cell Sci 112: 579-587, 1999. (Pubitemid 29106204)
10. Black RA, Rauch CT, Kozlosky CJ, et al: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385: 729-733, 1997. (Pubitemid 27098094)
11. Moss ML, Jin SL, Milla ME, et al: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385: 733-736, 1997. (Pubitemid 27098095)
12. Sahin U, Weskamp G, Kelly K, et al: Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164: 769-779, 2004. (Pubitemid 38282960)
13. Tsakadze NL, Sithu SD, Sen U, English WR, Murphy G and D'Souza SE: Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem 281: 3157-3164, 2006. (Pubitemid 43845925)
14. Garton KJ, Gough PJ, Philalay J, et al: Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem 278: 37459-37464, 2003. (Pubitemid 37175266)
15. Garton KJ, Gough PJ, Blobel CP, et al: Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276: 37993-38001, 2001.
16. Schramme A, Abdel-Bakky MS, Kampfer-Kolb N, Pfeilschifter J and Gutwein P: The role of CXCL16 and its processing metalloproteinases ADAM10 and ADAM17 in the proliferation and migration of human mesangial cells. Biochem Biophys Res Commun 370: 311-316, 2008.
17. Planque C, Kulasingam V, Smith CR, Reckamp K, Goodglick L and Diamandis EP: Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics 8: 2746-2758, 2009.
18. Oh ST, Schramme A, Stark A, Tilgen W, Gutwein P and Reichrath J: The disintegrin-metalloproteinases ADAM 10, 12 and 17 are upregulated in invading peripheral tumor cells of basal cell carcinomas. J Cutan Pathol 36: 395-401, 2009.
19. Kornfeld JW, Meder S, Wohlberg M, et al: Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression. Br J Cancer 104: 138-145, 2011.
20. Karan D, Lin FC, Bryan M, et al: Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int J Oncol 23: 1365-1371, 2003.
21. Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE and Chopp M: ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther 8: 1045-1054, 2009.
22. Hara T, Miyazaki H, Lee A, Tran CP and Reiter RE: Androgen receptor and invasion in prostate cancer. Cancer Res 68: 1128-1135, 2008.
23. Murphy G: The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 8: 929-941, 2008.
24. McGowan PM, Ryan BM, Hill AD, McDermott E, O'Higgins N and Duffy MJ: ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res 13: 2335-2343, 2007.
25. Glunde K and Stasinopoulos I: ADAM17: the new face of breast cancer-promoting metalloprotease activity. Cancer Biol Ther 8: 1055-1057, 2009.
26. McGowan PM, McKiernan E, Bolster F, et al: ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol 19: 1075-1081, 2008. (Pubitemid 351796332)
27. Franovic A, Robert I, Smith K, et al: Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17. Cancer Res 66: 8083-8090, 2006. (Pubitemid 44299174)
28. Gusterson BA: Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression. Eur J Cancer 28: 263-267, 1992.
29. Kenny PA: Three-dimensional extracellular matrix culture models of EGFR signalling and drug response. Biochem Soc Trans 35: 665-668, 2007.
30. Kenny PA: TACE: a new target in epidermal growth factor receptor dependent tumors. Differentiation 75: 800-808, 2007.
31. Shah RB, Ghosh D and Elder JT: Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence. Prostate 66: 1437-1444, 2006. (Pubitemid 44350369)
32. Harris RC, Chung E and Coffey RJ: EGF receptor ligands. Exp Cell Res 284: 2-13, 2003. (Pubitemid 36331964)
33. Seth D, Shaw K, Jazayeri J and Leedman PJ: Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells. Br J Cancer 80: 657-669, 1999. (Pubitemid 29209826)
34. De Haan AM, Wolters NM, Keller ET and Ignatoski KM: EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. Prostate 69: 528-537, 2009.
35. Ching KZ, Ramsey E, Pettigrew N, D'Cunha R, Jason M and Dodd JG: Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines. Mol Cell Biochem 126: 151-158, 1993. (Pubitemid 24004520)
36. Morris GL and Dodd JG: Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J Urol 143: 1272-1274, 1990. (Pubitemid 20193105)
37. Formento P, Hannoun-Levi JM, Gerard F, et al: Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft. Eur J Cancer 41: 1467-1473, 2005. (Pubitemid 40826472)
38. Mimeault M, Venkatraman G, Johansson SL, et al: Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int J Cancer 120: 160-169, 2007. (Pubitemid 44901931)
39. Wells A: EGF receptor. Int J Biochem Cell Biol 31: 637-643, 1999.
40. Grant S, Qiao L and Dent P: Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 7: d376-d389, 2002.
41. Majumder PK, Yeh JJ, George DJ, et al: Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci USA 100: 7841-7846, 2003. (Pubitemid 36760057)
42. Libra M, Scalisi A, Vella N, et al: Uterine cervical carcinoma: role of matrix metalloproteinases (Review). Int J Oncol 34: 897-903, 2009.
43. Roy R, Louis G, Loughlin KR, et al: Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 14: 6610-6617, 2008.
44. Wang Q, Diao X, Sun J and Chen Z: Regulation of VEGF, MMP-9 and metastasis by CXCR4 in a prostate cancer cell line. Cell Biol Int 35: 897-904, 2011.
45. Flaig TW, Gustafson DL, Su LJ, et al: A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 25: 139-146, 2007. (Pubitemid 46020872)
46. Nabeshima K, Inoue T, Shimao Y and Sameshima T: Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 52: 255-264, 2002. (Pubitemid 34587810)
47. Hwang MK, Song NR, Kang NJ, Lee KW and Lee HJ: Activation of phosphatidylinositol 3-kinase is required for tumor necrosis factor-alpha-induced upregulation of matrix metalloproteinase-9: its direct inhibition by quercetin. Int J Biochem Cell Biol 41: 1592-1600, 2009.
48. Aalinkeel R, Nair BB, Reynolds JL, et al: Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol Invest 40: 447-464, 2011.
49. Escaff S, Fernandez JM, Gonzalez LO, et al: Comparative study of stromal metalloproteases expression in patients with benign hyperplasia and prostate cancer. J Cancer Res Clin Oncol 137: 551-555, 2011.